3 Colo. Code Regs. § 712-1.18

Current through Register Vol. 47, No. 22, November 25, 2024

Section 3 CCR 712-1.18 - RULES REGARDING THE USE OF BENZODIAZEPINE

This Rule is promulgated pursuant to sections 12-20-204, 12-290-106(1)(a), and 12-30-109(6), C.R.S.

A. Licensees must limit any prescription for a continuous benzodiazepine to a 30-day supply, for any patient who has not been prescribed a benzodiazepine in the last 12 months.

Prior to prescribing the second fill of a benzodiazepine for a condition that is not exempt under section 12-280-404(4) (a.5) C.R.S., a licensee must comply with the requirements of section 12-280-404(4), C.R.S.

B. The limitation stated in Section (A) of this Rule does not apply to patients for whom licensees prescribe benzodiazepines for the following conditions:

1. Epilepsy;

2. A seizure, a seizure disorder, or a suspected seizure disorder;

3. Spasticity;

4. Alcohol withdrawal; or

5. A neurological condition, including a post-traumatic brain injury or catatonia.

C. These rules do not require or encourage abrupt discontinuation, limitation, or withdrawal of benzodiazepines. Licensees are expected to follow generally accepted standards of podiatry practice, based on an individual patient's needs, in tapering benzodiazepine prescriptions.

3 CCR 712-1.18

42 CR 14, July 25, 2019, effective 8/14/2019

45 CR 13, July 10, 2022, effective 7/30/2022

45 CR 22, November 25, 2022, effective 10/26/2022

45 CR 23, December 10, 2022, effective 11/11/2022

46 CR 02, January 25, 2022, effective 1/9/2023

46 CR 01, January 10, 2023, effective 1/30/2023